Table 4.

Adverse events (dose or time schedule)

Name of trial	Adverse event	Experimental arm (N)	Control arm (N)
CALGB 9712
	Anaemia grade 3/4	2/51	0/53
	Autoimmune haemolytic anaemia	0/51	1/53
	Chills grade 3/4	0/51	0/53
	Dyspnoea grade 3/4	7/51	3/53
	Fatigue/malaise grade 3/4	0/51	2/53
	Fever grade 3/4	0/51	0/53
	Hypotension grade 3/4	3/51	0/53
	Infections	10/51	12/53
	Myalgias grade 3/4	0/51	0/53
	Nausea grade 3/4	0/51	1/53
	Neurotoxicity	1/51	1/53
	Neutropenia grade 3/4	39/51	21/53
	Thrombocytopenia grade 3/4	10/51	5/53
	Vomiting grade 3/4	0/51	0/53
Wierda 2009
During treatment and up to 30 days following the last dose		FCO500	FCO1000
	Infections grade 3/4	4/31	7/30
	Febrile neutropenia grade 3/4	3/31	3/30
	Neutropenia	11/31	18/30
	Anaemia	2/31	6/30
	Thrombocytopenia	2/31	7/30
	Haemolytic anaemia grade 3/4	2/31	1/30